as of 11-28-2025 12:40pm EST
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | VANCOUVER |
| Market Cap: | 461.6M | IPO Year: | 2021 |
| Target Price: | $7.78 | AVG Volume (30 days): | 4.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.90 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.01 - $6.33 | Next Earning Date: | 11-12-2025 |
| Revenue: | $2,815,000 | Revenue Growth: | -33.09% |
| Revenue Growth (this year): | 40.12% | Revenue Growth (next year): | 331.37% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
SVP, CAO
Avg Cost/Share
$2.70
Shares
10,000
Total Value
$27,000.00
Owned After
180,428
SEC Form 4
Director
Avg Cost/Share
$2.66
Shares
95,785
Total Value
$254,788.10
Owned After
113,960
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Bedrick Todd | ABSI | SVP, CAO | Sep 22, 2025 | Buy | $2.70 | 10,000 | $27,000.00 | 180,428 | |
| Pangalos Menelas N | ABSI | Director | Sep 22, 2025 | Buy | $2.66 | 95,785 | $254,788.10 | 113,960 |
See how ABSI stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "ABSI Absci Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.